Saltar al contenido
MilliporeSigma

Small molecule-induced mitochondrial disruption directs prostate cancer inhibition via UPR signaling.

Oncotarget (2013-08-02)
Elizabeth Rico-Bautista, Wenhong Zhu, Shinichi Kitada, Suthakar Ganapathy, Eric Lau, Stan Krajewski, Joel Ramirez, Jason A Bush, Zhimin Yuan, Dieter A Wolf
RESUMEN

We previously identified SMIP004 (N-(4-butyl-2-methyl-phenyl) acetamide) as a novel inducer of cancer-cell selective apoptosis of human prostate cancer cells. SMIP004 decreased the levels of positive cell cycle regulators, upregulated cyclin-dependent kinase inhibitors, and resulted in G1 arrest, inhibition of colony formation in soft agar, and cell death. However, the mechanism of SMIP004-induced cancer cell selective apoptosis remained unknown. Here, we used chemical genomic and proteomic profiling to unravel a SMIP004-induced pro-apoptotic pathway, which initiates with disruption of mitochondrial respiration leading to oxidative stress. This, in turn, activates two pathways, one eliciting cell cycle arrest by rapidly targeting cyclin D1 for proteasomal degradation and driving the transcriptional downregulation of the androgen receptor, and a second pathway that activates pro-apoptotic signaling through MAPK activation downstream of the unfolded protein response (UPR). SMIP004 potently inhibits the growth of prostate and breast cancer xenografts in mice. Our data suggest that SMIP004, by inducing mitochondrial ROS formation, targets specific sensitivities of prostate cancer cells to redox and bioenergetic imbalances that can be exploited in cancer therapy.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
SMIP004-7, ≥98% (HPLC)